Fitness ranking of individual mutants drives patterns of epistatic interactions in HIV-1

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Martínez, Javier P ^a   Bocharov, Gennady ^b   Ignatovich, Anna ^b   Reiter, Jochen ^a   Dittmar, Matthias T ^c   Wain Hobson, Simon ^d   Meyerhans, Andreas ^a,e  

^a SAARLAND UNIVERSITY   (Germany)

^b INSTITUTE OF NUMERICAL MATHEMATICS   (Russian Federation)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d INSTITUT PASTEUR   (France)

^e UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; GENETIC EPISTASIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATIONAL ANALYSIS; NONHUMAN; NORMAL HUMAN; QUANTITATIVE ANALYSIS; VIRUS CELL INTERACTION; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE; DRUG EFFECT; GENETICS; MOLECULAR EVOLUTION; MUTATION; POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

ZIDOVUDINE;

EPISTASIS, GENETIC; EVOLUTION, MOLECULAR; HIV-1; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION; POLYMERASE CHAIN REACTION; VIRUS REPLICATION; ZIDOVUDINE;

EID: 79953669224     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018375     Document Type: Article

References (57)

1. Elena SF, Sole RV, Sardanyes J, (2010) Simple genomes, complex interactions: epistasis in RNA virus. Chaos 20: 026106.
2. Bateson W, (1909) Mendeĺs Principles of Heredity Cambridge University Press.
3. Kouyos RD, Silander OK, Bonhoeffer S, (2007) Epistasis between deleterious mutations and the evolution of recombination. Trends Ecol Evol 22: 308-315.
4. Michalakis Y, Roze D, (2004) Evolution. Epistasis in RNA viruses. Science 306: 1492-1493.
5. Gavrilets S, (2004) Fitness Landscapes and the Origin of Species Princeton University Press.
6. Carlborg O, Jacobsson L, Ahgren P, Siegel P, Andersson L, (2006) Epistasis and the release of genetic variation during long-term selection. Nat Genet 38: 418-420.
7. Badano JL, Leitch CC, Ansley SJ, May-Simera H, Lawson S, et al. (2006) Dissection of epistasis in oligogenic Bardet-Biedl syndrome. Nature 439: 326-330.
8. Cordell HJ, (2009) Detecting gene-gene interactions that underlie human diseases. Nat Rev Genet 10: 392-404.
9. Gregersen JW, Kranc KR, Ke X, Svendsen P, Madsen LS, et al. (2006) Functional epistasis on a common MHC haplotype associated with multiple sclerosis. Nature 443: 574-577.
10. Otto SP, Gerstein AC, (2006) Why have sex? The population genetics of sex and recombination. Biochem Soc Trans 34: 519-522.
11. de Visser JA, Elena SF, (2007) The evolution of sex: empirical insights into the roles of epistasis and drift. Nat Rev Genet 8: 139-149.
12. de Visser JA, Hermisson J, Wagner GP, Ancel Meyers L, Bagheri-Chaichian H, et al. (2003) Perspective: Evolution and detection of genetic robustness. Evolution 57: 1959-1972.
13. Ortlund EA, Bridgham JT, Redinbo MR, Thornton JW, (2007) Crystal structure of an ancient protein: evolution by conformational epistasis. Science 317: 1544-1548.
14. Burch CL, Chao L, (2004) Epistasis and its relationship to canalization in the RNA virus phi 6. Genetics 167: 559-567.
15. Silander OK, Tenaillon O, Chao L, (2007) Understanding the evolutionary fate of finite populations: the dynamics of mutational effects. PLoS Biol 5: e94.
16. Elena SF, (1999) Little evidence for synergism among deleterious mutations in a nonsegmented RNA virus. J Mol Evol 49: 703-707.
17. Crotty S, Cameron CE, Andino R, (2001) RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 98: 6895-6900.
18. Sanjuan R, Moya A, Elena SF, (2004) The contribution of epistasis to the architecture of fitness in an RNA virus. Proc Natl Acad Sci U S A 101: 15376-15379.
19. Tsetsarkin KA, McGee CE, Volk SM, Vanlandingham DL, Weaver SC, et al. (2009) Epistatic roles of E2 glycoprotein mutations in adaption of chikungunya virus to Aedes albopictus and Ae. aegypti mosquitoes. PLoS One 4: e6835.
20. Bonhoeffer S, Chappey C, Parkin NT, Whitcomb JM, Petropoulos CJ, (2004) Evidence for positive epistasis in HIV-1. Science 306: 1547-1550.
21. da Silva J, Coetzer M, Nedellec R, Pastore C, Mosier DE, (2010) Fitness epistasis and constraints on adaptation in a human immunodeficiency virus type 1 protein region. Genetics 185: 293-303.
22. Parera M, Fernandez G, Clotet B, Martinez MA, (2007) HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions. Mol Biol Evol 24: 382-387.
23. Parera M, Perez-Alvarez N, Clotet B, Martinez MA, (2009) Epistasis among deleterious mutations in the HIV-1 protease. J Mol Biol 392: 243-250.
24. van Opijnen T, Boerlijst MC, Berkhout B, (2006) Effects of random mutations in the human immunodeficiency virus type 1 transcriptional promoter on viral fitness in different host cell environments. J Virol 80: 6678-6685.
25. Elena SF, Carrasco P, Daros JA, Sanjuan R, (2006) Mechanisms of genetic robustness in RNA viruses. EMBO Rep 7: 168-173.
26. Rolland M, Brander C, Nickle DC, Herbeck JT, Gottlieb GS, et al. (2007) HIV-1 over time: fitness loss or robustness gain? Nat Rev Microbiol 5: C1.
27. Jung A, Maier R, Vartanian JP, Bocharov G, Jung V, et al. (2002) Multiply infected spleen cells in HIV patients. Nature 418: 144.
28. Havlir DV, Eastman S, Gamst A, Richman DD, (1996) Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol 70: 7894-7899.
29. Wang K, Mittler JE, Samudrala R, (2006) Comment on "Evidence for positive epistasis in HIV-1". Science 312: 848; author reply 848.
30. Sluis-Cremer N, Arion D, Parniak MA, (2000) Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs). Cell Mol Life Sci 57: 1408-1422.
31. Beerenwinkel N, Daumer M, Sing T, Rahnenfuhrer J, Lengauer T, et al. (2005) Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. J Infect Dis 191: 1953-1960.
32. Boyer PL, Sarafianos SG, Clark PK, Arnold E, Hughes SH, (2006) Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? PLoS Pathog 2: e10.
33. Lacey SF, Larder BA, (1994) Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance. J Virol 68: 3421-3424.
34. Neumann T, Hagmann I, Lohrengel S, Heil ML, Derdeyn CA, et al. (2005) T20-insensitive HIV-1 from naive patients exhibits high viral fitness in a novel dual-color competition assay on primary cells. Virology 333: 251-262.
35. Harrigan PR, Bloor S, Larder BA, (1998) Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol 72: 3773-3778.
36. Hu Z, Giguel F, Hatano H, Reid P, Lu J, et al. (2006) Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J Virol 80: 7020-7027.
37. Arts EJ, Quinones-Mateu ME, Albright JL, (1998) Mechanisms of clinical resistance by HIV-I variants to zidovudine and the paradox of reverse transcriptase sensitivity. Drug Resist Updat 1: 21-28.
38. Maeda Y, Venzon DJ, Mitsuya H, (1998) Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J Infect Dis 177: 1207-1213.
39. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, et al. (2000) A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 44: 920-928.
40. Richman D, Shih CK, Lowy I, Rose J, Prodanovich P, et al. (1991) Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci U S A 88: 11241-11245.
41. van Opijnen T, de Ronde A, Boerlijst MC, Berkhout B, (2007) Adaptation of HIV-1 depends on the host-cell environment. PLoS ONE 2: e271.
42. Arts EJ, Marois JP, Gu Z, Le Grice SF, Wainberg MA, (1996) Effects of 3′-deoxynucleoside 5′-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA. J Virol 70: 712-720.
43. Arts EJ, Wainberg MA, (1994) Preferential incorporation of nucleoside analogs after template switching during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother 38: 1008-1016.
44. Nowak AMM, R M, (2000) Virus Dynamics Oxford University Press Inc.
45. Althaus CL, Bonhoeffer S, (2005) Stochastic interplay between mutation and recombination during the acquisition of drug resistance mutations in human immunodeficiency virus type 1. J Virol 79: 13572-13578.
46. Kouyos RD, Otto SP, Bonhoeffer S, (2006) Effect of varying epistasis on the evolution of recombination. Genetics 173: 589-597.
47. Montville R, Froissart R, Remold SK, Tenaillon O, Turner PE, (2005) Evolution of mutational robustness in an RNA virus. PLoS Biol 3: e381.
48. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, et al. (1995) In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1: 1284-1290.
49. Gelderblom HC, Vatakis DN, Burke SA, Lawrie SD, Bristol GC, et al. (2008) Viral complementation allows HIV-1 replication without integration. Retrovirology 5: 60.
50. Arien KK, Vanham G, Arts EJ, (2007) Is HIV-1 evolving to a less virulent form in humans? Nat Rev Microbiol 5: 141-151.
51. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR, (1989) Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77: 51-59.
52. Graham FL, Smiley J, Russell WC, Nairn R, (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59-74.
53. Fletcher CV, Kawle SP, Kakuda TN, Anderson PL, Weller D, et al. (2000) Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS 14: 2137-2144.
54. Slusher JT, Kuwahara SK, Hamzeh FM, Lewis LD, Kornhauser DM, et al. (1992) Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure. Antimicrob Agents Chemother 36: 2473-2477.
55. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D, (1998) Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72: 2855-2864.
56. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896-1905.
57. Armitage PB, G. Matthews JNS, (2002) Statistical Methods in Medical Research Blackwell Science Ltd.